(85 days)
No
The summary describes a rule-based system for detecting arrhythmias based on ECG monitoring and does not mention AI or ML.
No.
The device's purpose is to monitor and alert clinicians of life-threatening cardiac events, not to directly treat or provide therapy to the patient.
No
The device is an alert system for clinicians, providing notifications of cardiac events detected from ECG monitoring. While it monitors and identifies specific conditions, its primary function is to alert, not to provide a diagnosis or aid in making a medical diagnosis. It focuses on notification of life-threatening cardiac events and arrhythmias, which are symptomatic findings rather than conclusive diagnoses. The predicate devices are also monitoring systems.
No
The device description explicitly states it is an "ambulatory ECG patient monitoring system," implying hardware components for ECG acquisition and monitoring, in addition to the software for analysis and alerting. The performance studies also mention compliance with safety and performance standards, which would typically apply to hardware as well as software.
Based on the provided information, the NetGuard Automated Clinician Alert System is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- NetGuard's function: The NetGuard system monitors a patient's ECG (electrocardiogram), which is a measurement of electrical activity in the heart. This is a physiological measurement taken directly from the patient's body, not a test performed on a sample taken from the body.
- Intended Use: The intended use clearly states it monitors a patient's ECG and issues alerts based on detected arrhythmias and heart rates. This is a form of in vivo monitoring, not in vitro testing.
Therefore, the NetGuard Automated Clinician Alert System falls under the category of a patient monitoring device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The NetGuard Automated Clinician Alert System is intended for use by licensed clinicians, within a health care facility, to provide notification of life threatening cardiac events in ambulatory adult patients including: Asystole Ventricular-Fibrillation NetGuard monitors a patient's ECG and issues an alert whenever these arrhythmias are detected. The NetGuard System also provides notification for high and low heart rates.
Product codes
DSI
Device Description
The NetGuard Automated Clinician Alert System is an ambulatory ECG patient monitoring system designed to provide clinicians notification of potentially lethal cardiac events in adult patients, within a healthcare facility.
The NetGuard System is a prescription device to be used by licensed clinicians in a healthcare facility. Departments where the device may be used include:
• Post Operative Recovery Room
• Emergency Department
• Medical/Surgical Patient Floors
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Adult patients
Intended User / Care Setting
Licensed clinicians, within a health care facility. Departments where the device may be used include: Post Operative Recovery Room Emergency Department Medical/Surgical Patient Floors
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The NetGuard System has been tested and found to be in compliance with recognized safety, performance and electromagnetic compatibility standards. The FDA guidance Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm (October 28, 2003), was utilized in the planning and conduct of all performance testing. A risk analysis has been developed to identify potential hazards and document the mitigation of the hazards. The device's software has been validated in accordance with the requirements set forth in the FDA Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices (May 11, 2005).
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Micropaq™ Vital Signs Monitor, Welch Allyn, K021681, Acuity® Central Monitoring Station, Welch Allyn, K052160
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.1025 Arrhythmia detector and alarm (including ST-segment measurement and alarm).
(a)
Identification. The arrhythmia detector and alarm device monitors an electrocardiogram and is designed to produce a visible or audible signal or alarm when atrial or ventricular arrhythmia, such as premature contraction or ventricular fibrillation, occurs.(b)
Classification. Class II (special controls). The guidance document entitled “Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm” will serve as the special control. See § 870.1 for the availability of this guidance document.
0
Image /page/0/Picture/0 description: The image shows the word "Datascope" in a bold, sans-serif font. Above the word is a curved line that arches over the entire word. The word is in black, and the background is white.
innovation is the best medicine
Ko71805 p / 2-
510(k) Summary SEP 2 6 2007 NetGuard Automated Clinician Alert System
This 510(K) Summary is provided in accordance with 21 CFR 807.92.
| Date: | June 29, 2007 |
|---|---|
| Submitter: | Datascope Corp. |
| 800 MacArthur Blvd. | |
| Mahwah, NJ 07430 | |
| Contact: Kathleen Kramer | |
| Supervisor, Clinical and Regulatory Affairs | |
| Telephone: 201-995-8169 | |
| Facsimile: 201-995-8605 | |
| Device Trade Name: | NetGuard Automated Clinician Alert System |
| Common Name: | Arrhythmia detector and Alarm |
| Device Classification: | Arrhythmia detector and Alarm |
| 21 CFR 870.1025, Product code: DSI, Class: II | |
| Predicate Devices: | Micropaq™ Vital Signs Monitor, Welch Allyn, K021681 |
| Acuity® Central Monitoring Station, Welch Allyn, K052160 | |
| Device description: | The NetGuard Automated Clinician Alert System is an ambulatory |
| ECG patient monitoring system designed to provide clinicians | |
| notification of potentially lethal cardiac events in adult patients, | |
| within a healthcare facility. |
The NetGuard System is a prescription device to be used by
licensed clinicians in a healthcare facility. Departments where the
device may be used include:
• Post Operative Recovery Room
• Emergency Department
• Medical/Surgical Patient Floors |
1
Image /page/1/Picture/0 description: The image shows the logo for Datascope. The logo features the word "Datascope" in a bold, sans-serif font. Above the word is a curved line that resembles an arc. The arc starts thick on the left side and thins out as it moves to the right.
K07 8,05 p2/2
The NetGuard Automated Clinician Alert System is intended for
innovation is the best medicine
Indications for Use:
use by licensed clinicians, within a health care facility, to provide notification of life threatening cardiac events in ambulatory adult patients including: . Asystole Ventricular-Fibrillation � NetGuard monitors a patient's ECG and issues an alert whenever these arrhythmias are detected. The NetGuard System also provides notification for high and low heart rates. Technological Comparison to Predicate Device: The NetGuard System is technically equivalent to Welch Allyn's Acuity Central Monitoring Station (K052160) and Micropaq Vital Signs Monitor (K021681) with respect to technical and performance characteristic including, but not limited to, transmitting frequency, data storage, patient management, data review, measured physiological parameters and alarm management. Summary of Performance Testing: The NetGuard System has been tested and found to be in compliance with recognized safety, performance and electromagnetic compatibility standards. The FDA guidance Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm (October 28, 2003), was utilized in the planning and conduct of all performance testing. A risk analysis has been developed to identify potential hazards and document the mitigation of the hazards. The device's software has been validated in accordance with the requirements set forth in the FDA Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices (May 11, 2005). Conclusion: Based on the above description, technological comparison, performance testing and the supporting documentation it can be concluded that the NetGuard device is safe, effective and substantially equivalent to the predicate device.
501(K) Summary
2
Image /page/2/Picture/1 description: The image shows the seal of the U.S. Department of Health and Human Services. The seal features a stylized caduceus, a symbol often associated with medicine and healthcare, with a series of curved lines resembling snakes intertwined around a staff. The seal is encircled by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
SEP 2 5 2007
Datascope Corp. c/o Ms. Kathleen Kramer Supervisor, Clinical and Regulatory Affairs 800 MacArthur Blvd. Mahwah, NJ 07430
Re: K071805
NetGuard Automated Clinician Alert System Regulation Number: 21 CFR 870.1025 Regulation Name: Arrhythmia detector and Alarm Regulatory Class: Class II (two) Product Code: DSI Dated: June 29, 2007 Received: July 2, 2007
Dear Ms. Kramer:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
3
Page 2 - Ms. Kathleen Kramer
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
M.A. Hillemann
An Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Indications for Use
510(k) Number (if known): Κολιθός
Device Name: NetGuard Automated Clincian Alert System
Indications For Use:
The NetGuard Automated Clinician Alert System is intended for use by licensed clinicians, within a health care facility, to provide notification of life threatening cardiac events in ambulatory adult patients including:
Asystole Ventricular-Fibrillation
NetGuard monitors a patient's ECG and issues an alert whenever these arrhythmias are detected. The NetGuard system also provides notification for high and low heart rates.
| Prescription Use | |
|---|---|
| (Part 21 CFR 801 Subpart D) | ✓ |
AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Mr. A. Willebronne
cular Devices
510(k) Number
Page 1 of ____________________________________________________________________________________________________________________________________________________________________